Androgen receptor in triple negative breast cancer: A potential target for the targetless subtypeLorenzo Gerratana, Grazia Arpino, Michelino De Laurentiis et al.|Cancer Treatment Reviews|2018Cited by 282
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?Giuseppe Buono, Fabio Puglisi, Lorenzo Gerratana et al.|Cancer Treatment Reviews|2019Cited by 124
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational studyGiuseppe Buono, Grazia Arpino, Anna Crispo et al.|Breast Cancer Research and Treatment|2020Cited by 70
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapyGrazia Arpino, Sabino De Placido, Carmine De Angelis et al.|Breast Cancer Research and Treatment|2015Cited by 49
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial resultsSabino De Placido, Grazia Arpino, Mario Giuliano et al.|The Breast|2018Cited by 35